← Leaderboards
Mingjiang Xu
Pennsylvania State Univ Hershey Med Ctr
$9,383,816
Attributed
$16,863,243
Total exposure
9
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2012–25$2.5M$1.9M$1.3M$625K$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,863,243 · 9
By mechanism
R01$16,493,275 · 8
R21$369,968 · 1
Top collaborators
- Feng-Chun Yang17 shared
- Suming Huang8 shared
- Jianlong Wang7 shared
- Chuan He2 shared
Most similar at Pennsylvania State Univ Hershey Med Ctr
Same institution · by research overlap
- Suming Huang$10,342,386
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingMutationRegulationMouse ModelCellsGenesHematopoiesisPathogenesisGene ExpressionHematopoieticHematopoietic Stem CellsBindingMyeloproliferative DiseaseMolecularSuccessIn VivoProteinsGenetic TranscriptionChromatinLeadBiologyPhysiologicalBehaviorMutate
Grant awards (39)
Critical roles of RNA m5C-MBD6-H2AK119ub deubiquitylation axis in TET2-mediated HSC regulation$703,040
R01 · FY2025 · HL · contact PI
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization$626,361
R01 · FY2025 · CA
Therapeutic value and mechanistic action of PSPC1 in AML$600,374
R01 · FY2025 · CA · contact PI
Critical roles of RNA m5C-MBD6-H2AK119ub deubiquitylation axis in TET2-mediated HSC regulation$717,415
R01 · FY2024 · HL · contact PI
Therapeutic value and mechanistic action of PSPC1 in AML$614,749
R01 · FY2024 · CA · contact PI
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization$595,044
R01 · FY2024 · CA
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$473,611
R01 · FY2024 · CA
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization$613,836
R01 · FY2023 · CA
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$232,957
R01 · FY2023 · CA
Role of lncRNA mediated R-loops in CTCF boundary function and AML genome organization$641,950
R01 · FY2022 · CA
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$561,228
R01 · FY2022 · HL · contact PI
Role of lincRNAs in HSC function and leukemogenesis$532,517
R01 · FY2022 · HL · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$413,948
R01 · FY2022 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$1
R01 · FY2022 · CA
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$558,814
R01 · FY2021 · HL · contact PI
Role of lincRNAs in HSC function and leukemogenesis$535,341
R01 · FY2021 · HL · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$413,488
R01 · FY2021 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$366,542
R01 · FY2021 · CA
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$557,606
R01 · FY2020 · HL · contact PI
Role of lincRNAs in HSC function and leukemogenesis$555,453
R01 · FY2020 · HL · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$412,845
R01 · FY2020 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$365,750
R01 · FY2020 · CA
Role of lincRNAs in HSC function and leukemogenesis$557,193
R01 · FY2019 · HL · contact PI
Roles of TET2-dependent DNA demethylation intermediates in hematological malignancies$555,796
R01 · FY2019 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$364,563
R01 · FY2019 · CA
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$340,628
R01 · FY2019 · HL · contact PI
TET2-mediated transcriptional and epigenetic control of normal and malignant hematopoiesis$80,084
R01 · FY2019 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2018 · CA
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2017 · CA
Role of TET2 in normal hematopoiesis and pathogenesis of myeloid malignancies$383,750
R01 · FY2016 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2016 · CA
Role of TET2 in normal hematopoiesis and pathogenesis of myeloid malignancies$377,993
R01 · FY2015 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$318,513
R01 · FY2015 · CA
No-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutations$200,318
R21 · FY2015 · CA
Role of TET2 in normal hematopoiesis and pathogenesis of myeloid malignancies$382,200
R01 · FY2014 · HL · contact PI
Role of Asxl1 in normal hematopoiesis and pathogenesis of myeloid malignancies$323,700
R01 · FY2014 · CA
No-nonsense approach to treat myeloid malignancies with ASXL1 nonsense mutations$169,650
R21 · FY2014 · CA
Role of TET2 in normal hematopoiesis and pathogenesis of myeloid malignancies$371,280
R01 · FY2013 · HL · contact PI
Role of TET2 in normal hematopoiesis and pathogenesis of myeloid malignancies$389,166
R01 · FY2012 · HL · contact PI